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Letters to the EditorReply to the Letter to the Editor ‘Effect of treatment with
polyunsatured fatty acids on HCV- or diet-induced fatty liver’This is a reply to the Letter to the Editor by Comparcola et al.
We appreciate Comparcola and colleagues for their comments
on our ﬁndings about the pathogenesis of lipid metabolism dis-
turbances in hepatitis C virus (HCV) infection [1]. The pathogen-
esis of hepatic steatosis in hepatitis C has been enthusiastically
investigated [2]. Several pathways have been described as mech-
anisms underlying steatogenesis in hepatitis C: the core protein
of HCV inhibits the secretion of very low density lipoprotein
(VLDL) from the liver by suppressing the function of microsomal
triglyceride transfer protein (MTP) [3], increases the production
of fatty acids by upregulating sterol regulatory element binding
protein (SREBP)-1c gene expression [4], and induces hepatic insu-
lin resistance resulting in the increased uptake of fatty acid into
the liver [5]. The combination of these events would lead to a fre-
quent development of steatosis in hepatitis C.
We thank Comparcola et al. for noting that NADH accumulation
is a characteristic feature of mitochondrial dysfunction in a NAFLD
model [6]. We propose that the accumulation of NADH due to dys-
function in themitochondrial electron transfer system (ETS)maybe
responsible for steatogenesis in HCV infection [1]. Interestingly,
tacrolimus, an immunosuppressive agent, reverses the inﬂuence
of the core protein, including hepatic steatosis and insulin resis-
tance, simultaneously with the restoration of mitochondrial ETS
function, as indicated by reduction of NADH accumulation, in a
mouse model [7]. This pathwaymay be a common one in the path-
ogenesis of NASH and hepatitis C, and could be a target for treat-
ment. Hepatitis C should be recognized as a metabolic disease as
well as a hepatic disease that manifests as insulin resistance and
lipid metabolism disorder, resembling NASH, as previously pro-
posed by our team [8] and Balsano et al. [9].
Of importance, exogenously administered polyunsaturated
fatty acids (PUFAs) improve the accumulation and altered com-
position of lipids caused by HCV [1], as well as those in non-alco-
holic fatty liver disease [10]. However, we would like to withhold
our consent for its application in hepatitis C patients, because
PUFAs did not reduce the NADH accumulation in our model sys-
tem, while pyruvate did [1].
Lastly, it is crucial for hepatologists to identify hepatitis C as a
metabolic disease, not only to guide patients toward improving
their life style, but also to invent ameasure to reverse themetabolic
disorders,which are the essential aggravating factors for hepatitis C.
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